Moleculin Biotech Inc expected to post a loss of 27 cents a share - Earnings Preview

Moleculin Biotech

09/08/2023 13:46

* Moleculin Biotech Inc  MBRX.OQ   MBRX.O  is expected
to show no
change in quarterly revenue when it reports  results on August
11. 
    * 
    * ​Refinitiv's mean analyst estimate for Moleculin Biotech
Inc is
for a loss of 27 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Moleculin
Biotech
Inc is $5​, above​ its last closing price of $0.60. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.25       -0.25      -0.28     Missed  -12
 Dec. 31 2023              -0.30      -0.23     Beat    24.2
 Sep. 30 2022  -0.27       -0.27      -0.30     Missed  -11.1​
 Jun. 30 2022  -0.25       -0.25      -0.24     Beat    4.6
 ​​Mar.        -0.21       -0.21      -0.24     Missed  -13.5
 31 2022                                                
 Dec. 31 2021              -0.21      -0.09     Beat    57.1​
 Sep. 30 2021  -0.20       -0.20      -0.15     Beat    25
 Jun. 30 2021  -0.19       -0.19      -0.15     Beat    19.6
 This summary was machine generated August 9 at 12:45 GMT.  All
figures in US dollars  unless otherwise stated